Increased tumor-specific CD8+ T-cell infiltration is how dual ICI therapy reduces tumor growth, and Janus kinase inhibitor (JAKi) supplementation enhances ICI resistance by changing the immunosuppressive TME [55]. This evidence concerns the gene CD8A and neoplasm.